CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Gene editing stocks drop as Intellia announces layoffs
Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...
Crispr Therapeutics AG: Strategic Pipeline Progress and Financial Strength Drive Buy Rating
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...
Correcting Genetic Spelling Errors With Next-Generation Crispr
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
ENDPOINTS NEWS6d
As­traZeneca, CRISPR tools sup­pli­er ink gene edit­ing en­zyme li­cens­ing deal
ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...
Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
Bengaluru biotech start-up opens lab to develop disease diagnostics with gene editing tech
The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...